A Phase 3 interventional study of tacrolimus and everolimus in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aims of the study was to evaluate the safety and efficacy of early introduction one month post-transplantation of everolimus associated to EC-MPS with tacrolimus discontinuation in de novo liver transplant recipients and to evaluate if it leads to a better renal function 6 month post-transplantation compared to standard treatment associating tacrolimus and EC-MPS.
The renal function was estimated by glomerular filtration rate.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
Drug: tacrolimus · Drug: Basiliximab · Drug: Mycophenolic Acid · Drug: Corticosteroids
From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest).
Drug: tacrolimus · Drug: everolimus · Drug: Basiliximab · Drug: Mycophenolic Acid · Drug: Corticosteroids
Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
Also known as: Prograf®
Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
Also known as: Certican® / RAD001
Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
Also known as: Simulect®
Dose of 1440 mg/day from transplantation to month 6 post- transplantation
Also known as: Myfortic®
Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
Change From Baseline (Randomization) in Renal Function
Change in renal function was measured by change in glomerular filtration rate (GFR). GFR calculated using the abbreviated modification of diet in renal disease (aMDRD) formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.
Time frame: Baseline, Week 24
Number of Patients With Treatment Failures
Incidence of treatment failures, assessed with composite criterion including treated biopsy proven acute rejection (tBPAR) with a rejection activity index (RAI) according to Banff classification \>3, graft loss or death at 6 months. Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.
Time frame: At week 12 and week 24
Number of Patients With Treated or Not Treated Biopsy Proven Acute Rejection (BPAR)
Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy.
Time frame: at 12 week and 24 week
Number of Patients Reported With Different Categories of Severity of BPAR According to Banff Classification
Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy. The severity of BPAR was categorized as : Mild (Banff grade I, RAI = 4 and 5) Moderate (Banff grade II, RAI = 6 and 7) Severe (Banff grade III, RAI = 8 and 9) Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.
Time frame: at 12 week and 24 week
Number of Patients With Treated or Untreated BPAR With RAI Score Greater Than 3
Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The patients with treated or untreated BPAR having RAI score \> 3 were reported in this end point.
Time frame: At 24 weeks
Number of Patients With Death or Graft Loss
The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.
Time frame: at week 24
Change From Baseline (Randomization) in Serum Creatinine
Change in serum creatinine concentrations from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.
Time frame: Baseline, Week 24
Change From Baseline (Randomization) in Urine Protein/Creatinine Ratio
Change in urine protein/creatinine ratio from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.
Time frame: Baseline, week 24
Change From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula
Creatinine clearance by the Cockcroft-Gault formula is computed in mL/min/1.73m\^2 from the creatinine clearance in mL/min by multiplying it by 1.73 and dividing it by the body surface area Baseline was Day 28 visit.
Time frame: Baseline, Week 24
Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula
Change in glomerular filtration rate was calculated using the MDRD abbreviated formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.
Time frame: Baseline, Week 24
Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula
GFR estimated by using the Chronic kidney disease- epidemiology (CKD-EPI) formula: eGFR (mL/min/1.73m\^2) = 141 \* min(C/K,1)\^ α \* max(C/K,1)\^-1.209 \* 0.993\^A \* 1.1018 (if male) \* 1.159 (if black) where C = serum creatinine (in mg/dL) ; A = Age (in years); K = 0.7 for women and 0.9 for men; α = -0.329 for women and -0.411 for men. Baseline was Day 28 visit.
Time frame: Baseline, Week 24
Number of Patients in Different Stages of Chronic Kidney Diseases According to the K/DOQI Classification System
Kidney disease outcomes quality initiative (K/DOQI) classification is based on glomerular filtration rate (GFR), abbreviated MDRD formula (mL/min/1.73m\^2) : Stage 1 : GFR \>= 90; Stage 2 = GFR was between 60-89; Stage 3 = GFR was between 30-59 ; Stage 4 = GFR was between 15-29; Stage 5 = GFR was \< 15 (or dialysis)
Time frame: At Week 24
Number of Patients With Any Adverse Events, Serious Adverse Events, Death and Premature Discontinuation
Baseline was Day 28 visit. This endpoint reports patients with total adverse events (any), serious adverse events, death and premature discontinuation.
Time frame: Baseline to 24 weeks
| Milestone | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Started | 95 | 93 |
| Safety set of population | 94 | 90 |
| Intent to treat population | 93 | 90 |
| Completed | 88 | 71 |
| Not completed | 7 | 22 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Administrative problem | 1 | 1 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Adverse event | 3 | 16 |
| Withdrew: Graft loss | 1 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 1 |
| Withdrew: Abnormal laboratory values | 1 | 0 |
Change in renal function was measured by change in glomerular filtration rate (GFR). GFR calculated using the abbreviated modification of diet in renal disease (aMDRD) formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.
| mL/min/1.73m^2 | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Change From Baseline (Randomization) in Renal Function | -13.29 ± 2.75 | 1.05 ± 2.81 |
Incidence of treatment failures, assessed with composite criterion including treated biopsy proven acute rejection (tBPAR) with a rejection activity index (RAI) according to Banff classification \>3, graft loss or death at 6 months. Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| week 12, Treatment failures - NO | 91 | 88 |
| week 12, Treatment failures - YES | 2 | 2 |
| week 24, Treatment failures - NO | 89 | 81 |
| week 24, Treatment failures - YES | 4 | 9 |
Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy.
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Week 12, Treated BPAR | 2 | 2 |
| Week 12, Not treated BPAR | 0 | 0 |
| Week 24, Treated BPAR | 2 | 8 |
| Week 24, Not Treated BPAR | 0 | 1 |
Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy. The severity of BPAR was categorized as : Mild (Banff grade I, RAI = 4 and 5) Moderate (Banff grade II, RAI = 6 and 7) Severe (Banff grade III, RAI = 8 and 9) Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Week 12: Mild | 1 | 1 |
| Week 12: Moderate | 1 | 1 |
| Week 12: Severe | 0 | 0 |
| Week 24: Mild | 1 | 5 |
| Week 24: Moderate | 1 | 3 |
| Week 24: Sever | 0 | 0 |
Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The patients with treated or untreated BPAR having RAI score \> 3 were reported in this end point.
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Not Treated BPAR: RAI score >3 | 0 | 0 |
| Not Treated BPAR: Missing RAI score | 0 | 1 |
| Treated BPAR: RAI score >3 | 2 | 8 |
The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Graft Loss | 1 | 0 |
| Death | 1 | 1 |
Change in serum creatinine concentrations from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.
| µmol/L | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Change From Baseline (Randomization) in Serum Creatinine | 7.2 ± 36.0 | -1.3 ± 38.53 |
Change in urine protein/creatinine ratio from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.
| mg/mmol | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Change From Baseline (Randomization) in Urine Protein/Creatinine Ratio | -2.3 ± 27.89 | 21.9 ± 92.00 |
Creatinine clearance by the Cockcroft-Gault formula is computed in mL/min/1.73m\^2 from the creatinine clearance in mL/min by multiplying it by 1.73 and dividing it by the body surface area Baseline was Day 28 visit.
| mL/min/1.73m^2 | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Change From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula | -9.0 ± 30.63 | 0.7 ± 25.65 |
Change in glomerular filtration rate was calculated using the MDRD abbreviated formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.
| mL/min/1.73m^2 | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula | -11.8 ± 34.01 | 0.1 ± 32.59 |
GFR estimated by using the Chronic kidney disease- epidemiology (CKD-EPI) formula: eGFR (mL/min/1.73m\^2) = 141 \* min(C/K,1)\^ α \* max(C/K,1)\^-1.209 \* 0.993\^A \* 1.1018 (if male) \* 1.159 (if black) where C = serum creatinine (in mg/dL) ; A = Age (in years); K = 0.7 for women and 0.9 for men; α = -0.329 for women and -0.411 for men. Baseline was Day 28 visit.
| mL/min/1.73m^2 | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula | -6.9 ± 20.11 | 2.4 ± 22.18 |
Kidney disease outcomes quality initiative (K/DOQI) classification is based on glomerular filtration rate (GFR), abbreviated MDRD formula (mL/min/1.73m\^2) : Stage 1 : GFR \>= 90; Stage 2 = GFR was between 60-89; Stage 3 = GFR was between 30-59 ; Stage 4 = GFR was between 15-29; Stage 5 = GFR was \< 15 (or dialysis)
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Stage 1 | 24 ± 27.89 | 41 ± 92.00 |
| Stage 2 | 34 | 29 |
| Stage 3 | 28 | 4 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
Baseline was Day 28 visit. This endpoint reports patients with total adverse events (any), serious adverse events, death and premature discontinuation.
| Patients | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Any Adverse events | 85 | 81 |
| Serious Adverse events | 28 | 42 |
| Death | 1 | 2 |
| At least one AE led to premature discontinuation | 4 | 18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus | — | 28/94 (29.8%) | 68/94 (72.3%) |
| Everolimus (RAD001) | — | 42/90 (46.7%) | 64/90 (71.1%) |
| Event | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| Liver transplant rejectionImmune system disorders | 3/94 | 5/90 |
| SepsisInfections and infestations | 0/94 | 5/90 |
| Biliary anastomosis complicationInjury, poisoning and procedural complications | 4/94 | 5/90 |
| DiarrhoeaGastrointestinal disorders | 4/94 | 1/90 |
| Renal failureRenal and urinary disorders | 4/94 | 3/90 |
| PancytopeniaBlood and lymphatic system disorders | 0/94 | 2/90 |
| General physical health deteriorationGeneral disorders | 1/94 | 2/90 |
| Hepatocellular injuryHepatobiliary disorders | 0/94 | 2/90 |
| Transplant rejectionImmune system disorders | 0/94 | 2/90 |
| Back painMusculoskeletal and connective tissue disorders | 0/94 | 2/90 |
| Event | Tacrolimus | Everolimus (RAD001) |
|---|---|---|
| CholestasisHepatobiliary disorders | 12/94 | 24/90 |
| Hepatocellular injuryHepatobiliary disorders | 4/94 | 16/90 |
| DiarrhoeaGastrointestinal disorders | 16/94 | 6/90 |
| NeutropeniaBlood and lymphatic system disorders | 14/94 | 9/90 |
| AnaemiaBlood and lymphatic system disorders | 7/94 | 12/90 |
| HypertensionVascular disorders | 12/94 | 7/90 |
| HypokalaemiaMetabolism and nutrition disorders | 2/94 | 11/90 |
| Renal failureRenal and urinary disorders | 11/94 | 3/90 |
| LeukopeniaBlood and lymphatic system disorders | 8/94 | 10/90 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/94 | 8/90 |
Randomized population
| Age, Continuous(Years) | Tacrolimus | Everolimus (RAD001) | Total |
|---|---|---|---|
| Mean | 55.5 ± 8.24 | 56.5 ± 8.59 | 56.0 ± 8.41 |
| Sex: Female, Male(Participants) | Tacrolimus | Everolimus (RAD001) | Total |
|---|---|---|---|
| Female | 14 | 14 | 28 |
| Male | 81 | 79 | 160 |
The record gives a start of Dec 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus